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Background: The aim of the present study is to examine the clinical indices related to cardiovascular risk
management of Greek patients with type 2 diabetes, before and after the major economic crisis that emerged in
the country.
Methods: In this retrospective database study, the medical records of patients with type 2 diabetes treated at three
diabetes outpatient centers of the national health system during 2006 and 2012 were examined. Only patients with
at least six months of follow-up prior to the recorded examination were included. The prescription cost was
calculated in Euros per patient-year (€PY).
Results: A total of 1953 medical records (938 from 2006 and 1015 from 2012) were included. There were no significant
differences in adjusted HbA1c, systolic blood pressure and HDL-C, while significant reductions were observed in LDL-C
and triglycerides. In 2012, a higher proportion of patients were prescribed glucose-lowering, lipid-lowering and
antihypertensive medications. Almost 4 out of 10 patients were prescribed the new incretin-based medications, while the
use of older drugs, except for metformin, decreased. A significant increase in the adjusted glucose-lowering prescription
cost (612.4 [586.5-638.2] €PY vs 390.7 [363.5-418.0]; p < 0.001) and total prescription cost (1306.7 [1264.6-1348.7] €PY vs 1122.3
[1078.1-1166.5]; p < 0.001) was observed. The cost of antihypertensive prescriptions declined, while no difference was
observed for lipid-lowering and antiplatelet agents.
Conclusions: During the economic crisis, the cardiovascular risk indices of Greek patients with type 2 diabetes being
followed in public outpatient diabetes clinics did not deteriorate and in the case of lipid profile improved. However, the
total prescription cost increased, mainly due to the higher cost of glucose-lowering prescriptions.
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Type 2 diabetes (T2D) is increasingly becoming more
prevalent throughout the world [1]. Nowadays, multifactor-
ial medical management of the disease is widely recom-
mended, in order to prevent its catastrophic complications
[2]. Multifactorial management includes intensive treat-
ment and implementation of strict targets for cardiovascu-
lar risk factors (CRF), namely, hyperglycemia, hypertension,
dyslipidemia and prothrombotic state [2].* Correspondence: sliatis@med.uoa.gr
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unless otherwise stated.We had previously reported that in Greek patients with
T2D, being regularly examined in diabetes outpatient
clinics of the Greek National Health System (GNHS), the
management of major modifiable CRF improved signifi-
cantly between 1998 and 2006. This improvement was as-
sociated with a 2.2 fold increase in the cost of the relevant
prescribed medications [3]. Although the increased pre-
scription cost could be partly attributed to the intensifica-
tion of therapy, it was, however, most likely driven by the
introduction of new and more expensive medications [3].
Similar trends have been observed in other countries as
well [4-6].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lowering medications has emerged, based on the incretin
phenomenon. Medications of this class, categorized as
dipeptidyl peptidase-IV inhibitors (DPP-IVi) and glucagon-
like peptide-1 receptor agonists (GLP-1RA), have been
widely prescribed in patients with T2D worldwide. In the
year 2009, a major economic crisis emerged in Greece,
leading to the implementation of a financial rescue plan
lead by the “Troika”, (the International Monetary Fund,
the European Commission, and the European Central
Bank), in collaboration with the Greek Government. The
“control” of GNHS-related expenses held a central role of
the plan, which included a radical health system reform.
There have been “signs” that health outcomes have wors-
ened since the crisis emerged, especially in vulnerable
groups [7], while one study reported a significant increase
in the prevalence of suicidal ideation and suicide attempts
[8]. Soon after the crisis explosion, negotiations between
the Greek government and the pharmaceutical companies
lead to consecutive reductions in virtually all medication
prices, reaching an average of 25-30%, compared to the
before-crisis costs. In addition, a generic-oriented drug pre-
scription policy has been promoted [9].
The aim of the present study is to compare the clinical
indices (glucose control, blood pressure and lipid profile)
indicating the level of CRF control, before (2006) and
during the Greek economic crisis (2012), as well as the
prescription cost of medications aiming at these factors,
during the same period.
Methods
Three major GNHS diabetes outpatient clinics, one lo-
cated in Athens and two in Piraeus participated in the
study. A Diabetes Center in Greece is defined as an out-
patient clinic running within general hospitals of the
GNHS, equipped with health professionals specialized in
the field of diabetes.
We compared the medical records of all patients who
were examined at the above centers during 2006, with
those who were examined at the same centers during
the first nine months of 2012. Only patients with at least
six months of follow-up by the medical staff of the same
center prior to the recorded visit and patients who had at
least one previous examination during this time period
were included. When more than one patient visit (fulfill-
ing the above criteria) was recorded during the same year,
the first one was included.
Patients with type 1 diabetes were excluded from the
study, based on indications existing on each patient’s file.
In addition, patients with “unknown” type of diabetes or
with indications such as “under investigation”, “sterinoid”
and “LADA” were excluded as well.
According to routine clinical practice in all the partici-
pating centers, an HbA1c measurement is performed atevery scheduled examination (usually every 3–4 months),
both in 2006 and 2012. In addition, a complete lipid pro-
file is routinely scheduled every six months. If an HbA1c
measurement and/or complete lipid profile (total choles-
terol, LDL, HDL and triglycerides) was missing, the next
examination of the patient was recorded. If no such
examination existed within the year under study, the pa-
tient was excluded.
Prescriptions were identified on the basis of physician’s
reporting on each medical record at the recorded visit. The
cost of medications was calculated in Euros per patient per
year (€PY). For both periods, the official Greek market
prices (as indicated on the medication’s market box) were
used. Due to the fact that, starting from 2009, consecutive
reductions in the prices of virtually all medications have
been applied, no correction for inflation was needed.
The study protocol was approved by the Ethics Com-
mittee of all three participating institutions (Ethics Com-
mittee at Laiko General Hospital, Ethics Committee at
Tzanio Hospital and Ethics Committee at Nikaia General
Hospital).
Statistical analysis
Analysis of the data was performed using the SPSS statis-
tical software package (IBM-SPSS 20.0). Categorical data
were compared using the chi-square test. Comparisons of
normally distributed data between groups were performed
by the independent samples Student’s t-test or by ANOVA.
Analysis of covariance (ANCOVA) was used in order to
adjust the compared means for confounders. Regarding
non-normally distributed data, the Mann Whitney U test
(two independent-samples) or the Kruskall-Wallis H test
was performed. P values (two-tailed) < 0.05 were consid-
ered statistically significant. All comparisons between 2012
and 2006 were performed after adjustment for age and
duration of T2D.
Results
Out of the initial review of 4124 patient records, 1953
were eligible for inclusion in the study (938 from 2006
and 1015 from 2012). Out of the 2171 excluded patients,
710 had type 1 diabetes, 654 had other types of diabetes
or prediabetes and 807 did not meet the follow-up inclu-
sion criteria. The main demographic characteristics of the
participants are shown in Table 1. The mean age, the me-
dian diabetes duration and the median follow-up period at
the diabetes center were all significantly higher in the
2012 group compared to the 2006 group (Table 1). The
body mass index (BMI), adjusted for age and duration of
diabetes, was significantly higher in 2012 as well.
CRF control
After adjustment for age and duration of diabetes, gly-
caemic control (HbA1c level) and systolic blood pressure
Table 3 Pattern of antidiabetic drug treatment in 2006
and 2012
Table 1 Main demographic characteristics of the
study participants
2006 2012 p
N of participants 938 1015
Gender (males, %) 483 (51.5) 549 (54.1) 0.3
Age (years) 64.5 [63.8-65.2] 67.3 [66.8-68.0] < 0.001
Duration of diabetes (years)* 9 [4-16] 12 [7-19] < 0.001
Duration of follow-up
(months)*
27.0 [17–38] 40.0 [18–57] < 0.001
BMI (Kg/m2)¥ 29.9 [29.5-30.3] 30.6 [30.2-31.0] 0.02
Data are shown as n (%) or mean value [95% CI]. *Median value [interquartile
range]. ¥Adjusted for age and duration of diabetes.
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On the other hand, lipid profile improved significantly,
in terms of total cholesterol, LDL-cholesterol (LDL-C)
and triglyceride levels, while HDL-cholesterol (HDL-C)
levels were similar. There was a small but statistically
significant decrease in diastolic blood pressure (DBP)
(Table 2). The proportion of patients achieving the target
of HbA1c <7% (53 mmol/mol) was 53.9% in 2012 versus
56.1% in 2006 (p = 0.3). The proportion of patients achiev-
ing the SBP target of < 140 mmHg was 59.8% and 59.7% re-
spectively (p = 0.9), while the target of LDL-C < 2.6 mmol/l
was achieved by 60.4% of patients in 2012, compared to
40.2% in 2006 (p < 0.001).2006 2012 P*
Lifestyle intervention only 38 (4.1) 11 (1.1) 0.001
OAD only 597 (63.6) 573 (56.5) 0.7
OAD Monotherapy** 165 (27.6) 182 (31.8) 0.4
Combination (2 drugs)** 307 (51.5) 245 (42.7)Pattern of drug treatment
Although the proportion of patients using non-insulin
vs. insulin-based treatments did not differ significantly
(after adjustment for age and diabetes duration), the choiceTable 2 Glycaemic, lipid and blood pressure profile in
2006 and 2012 after adjustment for age and duration
of diabetes
2006 2012 p
HbA1c (%) 7.0 [6.9-7.1] 7.0 [7.0-7.1] 0.7
HbA1c (mmol/mol) 53 [52–54] 53 [53–54]
Non-insulin treated 6.7 [6.6-6.7] 6.7 [6.6-6.8] 0.9
50 [49–50] 50 [49–51]
Insulin treated 7.6 [7.5-7.8] 7.6 [7.4-7.7] 0.5
60 [58–62] 60 [57–61]
SBP (mmHg) 135.4 [134.2-136.7] 134.4 [133.3-135.5] 0.2
DBP (mmHg) 77.2 [76.6-77.9] 76.2 [75.5-76.8] 0.03
TC (mmol/l) 4.9 [4.8-5.0] 4.4 [4.3-4.4] < 0.001
HDL-C (mmol/l) 1.3 [1.2-1.3] 1.2 [1.2-1.3] 0.3
LDL-C (mmol/l) 2.9 [2.9-3.0] 2.5 [2.5-2.6] < 0.001
TGL (mmol/l) 1.7 [1.6-1.7] 1.6 [1.5-1.6] 0.003
(Data are shown as mean value [95% CI]).
SBP: Systolic blood pressure, DBP: Diastolic blood pressure, TC: Total
cholesterol, TGL: Triglycerides.between the available glucose-lowering drug classes chan-
ged (Table 3). The use of metformin increased (80.4%,
compared to 66.8%), while the use of sulphonylureas de-
creased, from 44.3% in 2006 to 26.6% in 2012 (Table 3).
The use of TZDs and glinides decreased from 17% and
12.5% in 2006 to 4.9% and 2.7% respectively in 2012. Incre-
tin -based therapies (not available in Greece during 2006)
were prescribed to 38.5% of patients in 2012. Regarding
the use of insulin, a significant increase in the proportion
of patients treated with ≥ 3 injections was observed in
2012. In addition, patients treated with insulin analogs in-
creased significantly, reaching 72.9% of insulin-treated pa-
tients in 2012, compared to 49.8% in 2006 (Table 3).
The proportion of patients using antihypertensive drugs
increased from 74.7% in 2006 to 84.4% in 2012 (p = 0.03).
(Table 4). Among those treated for hypertension, the pro-
portion of patients using ≥ 2 antihypertensive class medi-
cations increased from 27.7% to 39.2% (p < 0.001). The
adjusted mean number of prescribed antihypertensive drug
classes per patient increased from 1.5 to 1.8 (p < 0.001).
The use of lipid-lowering medications increased from
61.2% in 2006 to 79.9% in 2012 (p < 0.001). The use of
statins increased from 56.2% to 75.8% (p < 0.001), while
the use of fibrates did not change (3.4% in 2006 andCombination (3 drugs)** 125 (20.9) 146 (25.5)
Metformin 627 (66.8) 816 (80.4) < 0.001
Sulphonylurea 416 (44.3) 270 (26.6) < 0.001
TZD 159 (17.0) 50 (4.9) < 0.001
Glinide 118 (12.5) 27 (2.7) < 0.001
Acarbose 73 (7.8) 22 (2.2) < 0.001
DPP-IV inhibitor 0 350 (34.5)
GLP-1 agonist 0 39 (3.8)
Insulin 303 (32.3) 432 (42.6) 0.09
1 injection# 91 (30.0) 126 (29.2) 0.001
2 injections# 118 (38.9) 83 (19.3)
≥ 3 Injections# 94 (31.1) 222 (51.5)
Insulin analog# 151 (49.8) 315 (72.9) <0.001
Units per Kg of body weight 0.5 (0.3) 0.5 (0.3) 0.87
Data are shown as n (%).
*Statistical significance was assessed after adjustment for age and duration
of diabetes.
**Percentage refers to those treated with OAD only.
#Percentage refers to those treated with insulin.
OAD: Oral antidiabetic drugs, TZD: thiazolidinediones, GLP-1: glucagon-like
peptide-1, DPP-IV: dipeptidyl peptidase-IV.
Table 4 Prescription cost per patient-year for all diabetes-related medications (€PY)
2006 2012 p
Glucose-lowering (all patients) 390.7 [363.5-418.0] 612.4 [586.5-638.2] < 0.001
Glucose-lowering (only treated patients) 405.3 [377.6-433.1] 621.1 [595.1-647.1] < 0.001
OAD only 324.9 [297.0-352.9] 504.5 [476.3-532.7] < 0.001
Insulin 553.8 [501.6-606.0] 763.8 [720.6-807.0] < 0.001
Excluding incretins 405.3 [501.6-606.0] 508.0 [474.7-541.3] < 0.001
Excluding incretins & adjusting for insulin analog use 442.4 [415.2-469.6] 463.2 [431.5-495.0] 0.34
Antihypertensive (all patients) 285.3 [270.6-300.1] 255.2 [241.1-269.2] 0.004
Antihypertensive (only treated patients) 371.5 [356.0-387.1] 318.7 [304.7-332.7] < 0.001
Lipid-lowering (all patients) 357.3 [335.0-379.5] 361.0 [339.9-382.1] 0.81
Lipid-lowering (only treated patients) 571.8 [547.2-596.4] 449.9 [429.5-450.3] < 0.001
Antiplatelet (all patients) 89.0 [75.8-102.1] 78.1 [65.6-90.7] 0.25
Antiplatelet (only treated patients) 169.8 [146.2-193.4] 146.4 [124.2-168.5] 0.16
Total 1122.3 [1078.1-1166.5] 1306.7 [1264.6-1348.7] < 0.001
Data are shown as mean [95% CI]. Treated patients are considered as those receiving the respective class of medication. All comparisons have been adjusted for
age and duration of diabetes.
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of ω-3 fatty acids and ezetimibe was observed (10.7% vs.
1.6% and 11.6% vs. 5.9%, both p < 0.001). Combining sta-
tins with any other lipid-lowering medication increased
from 9.4% in 2006 to 25.9% in 2012 (P < 0.001).
The proportion of patients being prescribed antiplate-
let medications did not change between 2006 and 2012
(52.2% vs. 51.1% respectively, p = 0.6). However, the pat-
tern of treatment changed substantially, showing a de-
cline in aspirin use (37.0% vs. 43.6%, p = 0.002) and an
increase in clopidogrel use (18.6% vs. 10.8%, p < 0.001).
The use of dual antiplatelet therapy increased by border-
line significance (4.8% vs. 3.1%, p = 0.06).Cost of treatment
As shown in Table 4, a significant increase in the total
prescription cost per patient-year was observed in 2012.
The mean total cost of all diabetes-related medications
increased by 20.9% (1324.1 ± 729.2 €PY vs. 1096. ± 634.0
€PY, p < 0.001). After adjustment for age and duration of
diabetes the difference declined to +16.4% (1306.7 €PY
vs. 1122.3 €PY, p < 0.001). A significant increase was ob-
served for glucose-lowering medications (56.7%), while a
non-significant 1.0% increase was found for lipid-lowering
medications. On the other hand, a significant 10.6% de-
cline in the cost of antihypertensive drugs and a non-
significant 12.2% decline in the cost of antiplatelet drugs
was observed.
The 2012 sub-group being treated with incretin-based
therapies (n = 389) had a 2.5-fold higher adjusted glucose-
lowering prescription cost, compared to patients using
older therapies (n = 504), after excluding insulin-only
treated patients (944.5 [903.8-985.2] €PY vs. 374.4 [338.6-410.2] €PY), while their adjusted HbA1c was slightly
higher (7.1 [7.0-7.2] vs. 7.0 [6.9-7.1], p = 0.13).
The relative contribution of glucose-lowering medica-
tions to the total prescription cost increased from 34.8%
in 2006 to 46.9% in 2012, while all the other diabetes-
related prescribed medications showed a decline in their
relative contribution (Figure 1).Discussion
The principle findings of this study are: 1) There is no
deterioration of clinical indices related to cardiovascular
risk factors of patients with T2D who are regularly visit-
ing public outpatient diabetes clinics, after the emer-
gence of a major economic crisis in Greece. 2) The cost
of medications prescribed for cardiovascular risk man-
agement of these patients increased by 15% in 2012
(during the crisis), compared to 2006 (before the crisis).
We had previously reported that glycaemic control of
patients with T2D, who were examined in diabetes out-
patient clinics, improved by approximately one HbA1c %
unit between the years 1998 and 2006 [3]. The HbA1c im-
provement had been attributed to several factors, but per-
haps, most importantly, to the publication of the UKPDS
trial results, showing that intensive treatment of hypergly-
cemia has beneficial effect on diabetes complications [10].
Moreover, in 2006 we had observed a modest reduction in
blood pressure and a striking reduction in LDL-C of T2D
patients, due to a more intensified antihypertensive ther-
apy and to the widespread use of statins. These improve-
ments can be attributed to the wide implementation of
multifactorial management, which had been shown to de-
crease substantially both morbidity and mortality, associ-
ated with T2D [11].
Table 5 Comparison of medication prices between 2007
(before the economic crisis) and 2012 (during the crisis)
for key diabetes-related medications
2007 2012 % reduction
Metformin 1700 mg 4.6 4.2 −9.5
Glimepiride 3 mg 15.0 9.8 −34.7
Glimepiride 3 mg [generic] 12.0 8.8 −26.7
Pioglitazone 30 mg 65.2 45.1 −30.8
Insulin Glargine 1500 i.u.* 84.5 63.7 −24.6
Insulin Premixed 30/70 (Human)** 33.7 30.8 −8.6
Ramipril 5 mg 18.9 14.5 −23.3
Indapamide 1.5 mg 9.2 7.4 −19.6
Amlodipine 10 mg [generic] 22.8 11.3 −50.4
Simvastatin 40 mg 55.9 35.9 −35.8
Atorvastatin 20 mg [generic] 41.7 20.4 −51.1
Aspirin 100 mg 1.2 1.5 +25
Clopidogrel 75 mg 67.9 32.5 −52.1
Price is referred to € per 30-day treatment.
*Prefilled pen. **Cartridges.
Figure 1 Relative contribution on prescription cost of each
class of medications used for the management of
cardiovascular risk factors.
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no further decline in the mean adjusted HbA1c and SBP
values have been observed. The proportion of patients
achieving HbA1c <7% (53 mmol/mol) has remained
stable at around 50%, as well as that of patients achieving
SBP < 140 mmHG, at around 60%. In the USA National
Health and Nutrition Examination Survey (NHANES) co-
hort, there was no further improvement in glycaemic con-
trol between 2003/2006 and 2007/2010, while, similarly to
our results, a significant increase in the proportion of
patients achieving an HbA1c < 7% (53 mmol/mol) was
observed between 1999/2000 and 2003/2006 [12]. This
might be due to several factors. The enthusiasm pro-
duced after the publication of the UKPDS results in
1998 in contrast to the skepticism, generated from the
ACCORD and VADT trials in 2009, might be an explan-
ation. On the other hand, in the case of Greece, the eco-
nomic crisis might have contributed as well. It should be
emphasized, however, thet the LDL-C target of <100 mg/dl(2.6 mmol/l) was achieved, by 60% of patients in 2012,
compared to only 40% in 2006, a finding that can be clearly
attributed to the continuing spread of statin use (Table 3).
It has been speculated that the economic crisis might
deteriorate health status of Greek citizens due to auster-
ity and deprivation of health care resources [9,13]. Due
to the financial crisis, the Greek government negotiated
with pharmaceutical companies and decided a “haircut”
for most licensed medications in the Greek market that
reached an average of 30% compared to pre-crisis [9].
Importantly, during the crisis, the GNHS continued to
reimburse 90% of prescription cost regarding all licensed
medications for T2D, including incretin-based therapies
and insulin analogs.
In Table 5, the prices before and after the crisis explo-
sion are shown for some key medications, commonly
used for the treatment of T2D [14]. Despite the price re-
duction, however, according to our results, the total pre-
scription cost for T2D increased significantly in 2012.
As clearly shown in Table 4, the prescription cost related
to lipid-lowering, and antiplatelet medications did not
virtually change, despite that a higher proportion of patients
were prescribed lipid-lowering medications. Furthermore,
the prescription cost of antihypertensive medications de-
creased significantly despite intensification of antihyper-
tensive therapy (Table 4). On the contrary, the adjusted
prescription cost of glucose-lowering medications increased
by 56.7% (Table 4). Taking into account that the price of all
the older glucose-lowering medications decreased in 2012
(Table 5), it can be assumed that the prescription cost rise
is (at least partly) drawn by the introduction of new and
more expensive medications. Indeed, when patients taking
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(Table 4), the glucose-lowering prescription cost difference
between 2006 and 2012 dropped to +25.3%, still highly
significant. However, when further adjusting for the use
of insulin analogs (Table 4), the difference between 2006
and 2012 almost disappeared and became non-significant
(+4.7%, p = 0.34).
Insulin analogs have been associated with a lower risk
of hypoglycemia than older human insulins [15,16]. Since
the mid 00’s, several compounds based on the incretin
phenomenon have been added in the armamentarium of
glucose-lowering medications. Two GLP-1 analogs (exena-
tide and liraglutide) and three DPP-IV inhibitors (sitagliptin,
vildagliptin and saxagliptin) have been introduced in the
global and the Greek market as new glucose-lowering
agents. Although in the 2009 American Diabetes Asso-
ciation/European Association for the Study of Diabetes
(ADA/EASD) consensus statement on management of
hyperglycemia, only exenatide was included as second
or third line option treatment for T2D [17], the subse-
quent 2012 ADA/EASD position statement has assigned
to all incretin-based therapies a central role in T2D
management [18]. In many countries nowadays, GLP-1
based therapies hold a considerable share in diabetes-
related prescriptions [19,20]. The main advantage of
incretin-based medications is a neutral (with DPP-IV inhib-
itors) or favorable (with GLP-1 agonists) effect on body
weight and the lack of significant risk for hypoglycemia. On
the other hand, incretin-based therapies do not seem to be
more potent than previously existing medications in terms
of HbA1c reduction, while there is some concern regarding
their possible association with acute and/or chronic pan-
creatitis and α-cell hyperplasia [21-23]. In our 2012 group
the HbA1c of patients receiving incretin-based therapies
did not differ from those taking older drugs. Unfortunately,
we were not able to estimate hypoglycemic episodes, since
they were not reliably recorded. The BMI of patients receiv-
ing incretin-based drugs was actually higher, compared to
those under older oral antidiabetic agents, but this can be
attributed to indication bias.
Cost-utility analysis in the UKPDS study [24] showed
that tight vs. less tight blood pressure (BP) control, as
well as intensive vs. conventional glucose control, was
highly cost-effective. A cost-effectiveness study based on
the results of the Steno-2 trial demonstrated that in pa-
tients with T2D at high risk for CVD, multifactorial
intervention aiming at strict control of major risk factors
for CVD can be cost-effective, especially if administered
in a primary care setting [25].
Cost-effectiveness of the new therapies is under inves-
tigation [26,27]. It has been repeatedly reported that the
largest components of medical expenditures attributed
to diabetes are associated with treatment of complica-
tions (hospital inpatient care and medications to treatthese complications) rather than direct prescription cost
to treat hyperglycemia [28,29]. Hence it can be argued
that the benefit derived from reduced incidence of hypo-
glycemia (including severe hypoglycemia) and reduction
(or at least not increase) of body weight counterbalance
the higher medication price. Prospective studies with
hard diabetes-related endpoints and independent cost-
effectiveness studies of high quality are needed to estab-
lish cost-utility of new therapies. Our study, due to its
retrospective design, cannot be used to draw conclusions
concerning cost-effectiveness calculations. In any case,
current guidelines issued by the ADA/EASD and the
American Association of Clinical Endocrinologists en-
courage the use of GLP-1 based therapies as second-line
options [18,30].
The main limitation, of the present analysis is the
questionable representativeness of the study population.
A diabetes center in Greece is defined as an outpatient
diabetes clinic running within a public or university gen-
eral hospital, equipped with health professionals special-
ized in the field of diabetes. Any person regardless of
having a public insurance or not, may have an appoint-
ment and examination at these centers, with a wait time
of 2-4 months. For those not being insured, there is a 5€
charge that includes full medical examination and one
finger-stick glucose measurement. Due to the lack of an
organized primary care system in Greece, many patients
use the hospital outpatient clinics as a substitute for pri-
mary care management, even for reasons of drug pre-
scription. The patient population consists mainly of lower
socio-economic status and unemployed individuals, as
well as pensioners, while employers are a minority, mainly
because the outpatient clinics function only during the
morning. We cannot exclude, however, the possibility that
several patients, especially in the midst of a major eco-
nomic crisis, may not afford a 5€ fee. Furthermore, un-
employed/uninsured patients may not visit the diabetes
clinics, due to their inability to meet financial obligations
associated with medical advises/prescriptions. Costs asso-
ciated with transportation might be a barrier as well. In
addition, patients followed by general practitioners or
in the private setting are not included in this analysis.
In summary, although not representative of the whole
Greek T2D population, the study participants cover a broad
range of middle to low socioeconomic class patients.
Conclusions
In conclusion, we observed that during the Greek eco-
nomic crisis, cardiovascular risk management indices of
T2D patients being examined at three major diabetes
outpatient clinics of the GNHS, did not deteriorate and
in the case of LDL-C and triglycerides, they improved. A
15% increase in the associated total prescription cost
was observed, mainly due to the higher cost of glucose-
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http://www.biomedcentral.com/1472-6823/14/23lowering related medications. The introduction of new
medications in this field (as opposite to the unchanged
armamentum against hypertension, dyslipidemia and
hyperthrombotic state), although responsible for the in-
creased direct cost, might, on the other hand, provide
long-term benefits associated with a favorable profile in
terms of hypoglycemic risk and body weight. Long-term
prospective studies with hard diabetes-related endpoints
and independent cost-effectiveness studies of high qual-
ity are needed in order to clarify cost-effectiveness of
new therapies.
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